Quarterly results round-up: LabCorp, Bard hit by legal costs; Edwards, Intuitive grow top and bottom lines
This article was originally published in Clinica
Executive Summary
CR Bard swung to a net loss of $47.8m in its fiscal second quarter as it absorbed $195.5m in litigation charges related to its recalled hernia products. The products include the Composix Kugel mesh hernia patch, which its Davol subsidiary recalled in 2006 due to a risk of the patch breaking and damaging patients' internal organs (www.clinica.co.uk, 10 March 2006).